Clinical Trials Browser

talazoparib × Breast × 90 days × Clear all

NCT04550494 2026-05-13

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Phase 2 Recruiting

BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms

NCT01042379 2026-05-06

I-SPY

Phase 2 Recruiting

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT03990896 2026-05-06

Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial

Phase 2 Recruiting

Breast Neoplasms

NCT03964532 2026-04-09

TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer

Phase 1/2 Active not recruiting

Breast Neoplasms

NCT04039230 2026-03-16

Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.

Phase 1/2 Active not recruiting

Breast Neoplasms